- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (228)
- Breast Cancer (712)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (98)
- Ovarian Cancer (172)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (234)
- Skin Cancer (294)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (622)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (224)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (116)
- Molecular Diagnostics (8)
- Pain Management (64)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (880)
- Research (384)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (598)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (324)
- Symptoms (182)
- Treatment (1764)
Gynecologic oncologist: Specialization let me achieve my professional dream
3 minute read | Published November 05, 2018
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on November 05, 2018
As a gynecologic oncologist, I see women with every type of cancer related to the female reproductive system, except breast cancer. I treat women with ovarian, uterine, cervical, and vulvar cancers. And I routinely perform surgery, prescribe chemotherapy and suggest clinical trials.
I decided to specialize in gynecologic oncology after figuring out what was really important to me in medical school. I realized one day that I didn’t just want to operate on my patients. I wanted to take care of them long-term. Being a gynecologic oncologist allows me to do that: I see women from the time they’re diagnosed though their whole cycle of cancer care. And that is really satisfying.
What goes into every diagnosis
Part of each new patient’s evaluation process is obtaining the imaging, pathology slides and reports from any previous treatment, so that our pathologists and radiologists can review them. Because about 20% of the time, the diagnosis we render is slightly different from the one patients got originally. And that difference can change our treatment recommendations.
That’s why a lot of people come to MD Anderson: for a fresh set of eyes. But my patients aren’t just getting my personal opinion. We have 23 full-time gynecologic oncologists on staff. And I rely on my colleagues and their expertise to help me provide each patient with the best possible options to choose from.
Every time I make a recommendation, I consider the current standard of care, as well as any clinical trials available. Those could deal with new therapies or new combinations of existing therapies. Sometimes, there’s even a novel treatment that’s only available here at MD Anderson.
Helping women weigh their options
I try to have a discussion with every woman right after her diagnosis, to see what options she wants to hold onto. That way, we can weigh her wishes against the treatment opportunities available, and explore any fertility sparing options, if she’s of childbearing age and has a relatively low-risk cancer.
Fertility preservation has become more of a concern, as we’re seeing cancer in younger and younger patients. Historically, doctors have only looked ahead a few years when taking care of cancer patients. Today, they’re paying more attention to survivorship, and how patients are doing 10, 15 or even 20 years after diagnosis.
What keeps us going
I love my job. It gives me a unique opportunity to take care of women. Curing patients is obviously very rewarding, but so is helping them figure out the right choices for themselves. We’re giving our patients peace of mind that they’re making the right decisions, whatever those may be.
I’ve seen more clinical trials and treatments become available over the past 15 years than ever before. A number of new treatments have been approved in the last two years alone, and there are others on the horizon that could also have a significant impact on patients’ lives. As a physician, that’s what drives me: the opportunity to give hope to other patients.
Pamela Soliman, M.D., is a gynecologic oncologist at MD Anderson.
Request an appointment at MD Anderson online or by calling 1-866-326-0653

We’re giving our patients peace of mind.
Pamela Soliman, M.D.
Physician